{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "21094874",
  "DateCompleted": {
    "Year": "2011",
    "Month": "03",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.transproceed.2010.07.090"
    ],
    "Journal": {
      "ISSN": "1873-2623",
      "JournalIssue": {
        "Volume": "42",
        "Issue": "9",
        "PubDate": {
          "Year": "2010",
          "Month": "Nov"
        }
      },
      "Title": "Transplantation proceedings",
      "ISOAbbreviation": "Transplant Proc"
    },
    "ArticleTitle": "Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.",
    "Pagination": {
      "StartPage": "3871",
      "EndPage": "3875",
      "MedlinePgn": "3871-5"
    },
    "Abstract": {
      "AbstractText": [
        "Non-melanoma skin cancers (NMSCs) are the most common malignancies after solid organ transplantation. Their incidence increases with time after transplantation. Calcineurin-inhibitors (CNIs) and azathioprine are known as skin neoplasia-initiating and -enhancing immunosuppressants. In contrast, increasing clinical experience suggests a relevant antiproliferative effect of mammalian target of rapamycin inhibitors, also named proliferation signal inhibitors (PSIs). We report the case of a cardiac allograft recipient with an impressive and consolidated reduction of recurrent NMSC, observed after conversion from CNI-therapy to a PSI-based protocol."
      ],
      "CopyrightInformation": "Copyright \u00a9 2010 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern, Bern, Switzerland."
          }
        ],
        "LastName": "Signorell",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Hunziker",
        "ForeName": "T",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Martinelli",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Koestner",
        "ForeName": "S C",
        "Initials": "SC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Mohacsi",
        "ForeName": "P J",
        "Initials": "PJ"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Transplant Proc",
    "NlmUniqueID": "0243532",
    "ISSNLinking": "0041-1345"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Calcineurin Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    },
    {
      "RegistryNumber": "9HW64Q8G6G",
      "NameOfSubstance": "Everolimus"
    },
    {
      "RegistryNumber": "EC 2.7.1.1",
      "NameOfSubstance": "MTOR protein, human"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "TOR Serine-Threonine Kinases"
    },
    {
      "RegistryNumber": "W36ZG6FT64",
      "NameOfSubstance": "Sirolimus"
    },
    {
      "RegistryNumber": "WM0HAQ4WNM",
      "NameOfSubstance": "Tacrolimus"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Calcineurin Inhibitors"
    },
    {
      "QualifierName": [
        "enzymology",
        "etiology",
        "pathology",
        "therapy"
      ],
      "DescriptorName": "Carcinoma, Squamous Cell"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Cell Proliferation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Everolimus"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Heart Transplantation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Recurrence, Local"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Photochemotherapy"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Signal Transduction"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Sirolimus"
    },
    {
      "QualifierName": [
        "enzymology",
        "etiology",
        "pathology",
        "therapy"
      ],
      "DescriptorName": "Skin Neoplasms"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "TOR Serine-Threonine Kinases"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Tacrolimus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transplantation, Homologous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}